Medical Marijuana May Impair Thinking of MS Patients

March 28, 2011 -- Many multiple sclerosis (MS) patients use marijuana to ease pain and other symptoms associated with the disorder, but the practice might make one common symptom worse.

MS patients in a small study who smoked or ingested marijuana regularly for many years were twice as likely as non-users to show significant evidence of cognitive impairment when subjected to a battery of tests that measure thinking skills.

The study was published in the journal Neurology.

By some estimates, as many as 60% of patients with multiple sclerosis have some problems with attention, learning, or memory, ranging from mild to severe.

Study researcher Anthony Feinstein MD, PhD, of the Sunnybrook Health Services Center and the University of Toronto, says patients who use marijuana risk exacerbating these symptoms.

“Whatever benefits patients feel they might be getting from smoking marijuana might come at the cost of further cognitive compromise,” Feinstein tells WebMD.

Advocate of Medical Marijuana

Former talk-show host and multiple sclerosis patient Montel Williams is a daily marijuana user and a vocal advocate for the legalization of medical marijuana.

Williams has lobbied lawmakers in more than a dozen states, and he tells WebMD that medicinal marijuana gave him his life back after narcotic pain drugs like morphine and OxyContin almost shut down his liver and kidneys.

He delivered the same message in an episode of the syndicated medical program “The Dr. Oz Show,” scheduled to air this week.

“I have had this diagnosis for the last 10 years and I have also continued to be a contributing, tax-paying member of society,” Williams said. “[Marijuana] is what has allowed me to continue to work and continue to pay taxes.”

Marijuana Use and Mental Performance

The study included 25 MS patients who reported smoking or ingesting marijuana regularly for many years and an equal number of MS patients who did not use marijuana. The two groups were matched for age, sex, education level, IQ before diagnosis, level of disability, and duration of MS.

Feinstein says the study did not include patients who took synthetic cannabinoid, such as the pill Marinol, because these treatments did not have a psychoactive component and patients tend to prefer the real thing.

The average duration of marijuana use among the users studied was 26 years. Seventy-two percent of users reported using marijuana daily; 24% reported weekly use.

All study participants underwent a series of tests used to measure various aspects of mental functioning, including working memory, speed of information processing, and visual perception of spatial relationships. Study participants who used marijuana were not tested if last use was less than 12 hours before testing.

Feinstein says the marijuana users performed significantly worse than the non-users on tests measuring attention, speed of thinking, visual perception, and cognition related to planning and organizing.

Scores on one test measuring speed of processing information were about a third lower among marijuana users compared to non-users.

Thirty-two percent of non-users and 64% of users met the definition of globally cognitively impaired, meaning that they had measurable impairments in two or more aspects of intellectual functioning.